Eloralintide  (Synonyms: LY-3841136)

Eloralintide (LY 3841136) is an AMYR agonist, which is promising for research of type 2 diabetes and obesity^[1].

4526.10

C₂₀₁H₃₁₉N₄₉O₆₅S₂

2883634-40-8

{γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Methylene bridge: Cys2-Cys7)

{γGlu}-CNTATCATG-{Orn}-LAE-{(α-Me-Phe)}-LVRSSN-{(N-Me-Asn)}-FGP-{Lys(γGlu-γGlu-C20 diacid)}-LPPTEVGSNTY-NH2 (Methylene bridge: Cys2-Cys7)

OC1=CC=C(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]2N(CCC2)C([C@H]3N(CCC3)C([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C(CNC([C@@H](NC([C@@H](N(C)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@](C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC5=O)CC(N)=O)=O)[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CSCSC[C@@H]5NC(CC[C@H](N)C(O)=O)=O)=O)C)=O)[C@@H](C)O)=O)=O)CCCN)=O)CC(C)C)=O)C)=O)CCC(O)=O)=O)CC6=CC=CC=C6)=O)CC(C)C)=O)C(C)C)=O)CCCNC(N)=N)=O)CO)=O)CO)=O)CC(N)=O)=O)CC(N)=O)=O)CC7=CC=CC=C7)=O)=O)=O)CCCCNC(CC[C@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(O)=O)=O)=O)CC(C)C)=O)=O)=O)[C@@H](C)O)=O)CCC(O)=O)=O)C(C)C)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O)C(N)=O)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes.